Titre :

Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years

Auteur(s) :

Alidjinou, Enagnon Kazali [Auteur]
Pathogenèse virale du diabète de type 1 - ULR 3610
Demaret, Julie [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Corroyer-Simovic, Bénédicte [Auteur]
Labreuche, Julien [Auteur]
Service de Biostatistiques [CHRU Lille]
Goffard, Anne [Auteur]
Institut Pasteur de Lille
Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017
Trauet, Jacques [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Lupau, Daniela [Auteur]
Miczek, Sophie [Auteur]
Vuotto, Fanny [Auteur]
Dendooven, Arnaud [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Huvent-Grelle, Dominique [Auteur]
Podvin, Juliette [Auteur]
Dreuil, Daniel [Auteur]
Faure, Karine [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Deplanque, Dominique [Auteur]
Centre d'Investigation Clinique - Innovation Technologique de Lille - CIC 1403 - CIC 9301 [CIC Lille]
Bocket, Laurence [Auteur]
Pathogenèse virale du diabète de type 1 - ULR 3610
Duhamel, Alain [Auteur]
Santé Publique : épidémiologie et qualité des soins [EA 2694]
Sobaszek, Annie [Auteur]
IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483
Hober, Didier [Auteur]
Pathogenèse virale du diabète de type 1 - ULR 3610
Hisbergues, Michael [Auteur]
Puisieux, Francois [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hisbergues, Michael [Auteur]
Yazdanpanah, Yazdan [Auteur]
Labalette, Myriam [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Lefevre, Guillaume [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Titre de la revue :

The Lancet Regional Health - Europe

Nom court de la revue :

Lancet Reg Health Eur

Numéro :

17

Pagination :

100385

Éditeur :

Elsevier

Date de publication :

2022-04-21

ISSN :

2666-7762

Mot(s)-clé(s) en anglais :

BNT162b2 vaccine
Boost
SARS-CoV-2
Delta
Omicron
Older people
immunogenicity

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Background The present study aimed to evaluate the persistent immunogenicity offered by a third dose of BNT162b2 against Delta and Omicron variants, in nursing home (NH) residents. Methods In this monocenter prospective ...
Lire la suite >Background The present study aimed to evaluate the persistent immunogenicity offered by a third dose of BNT162b2 against Delta and Omicron variants, in nursing home (NH) residents. Methods In this monocenter prospective observational study, anti-spike IgG levels, S1 domain reactive T cell counts, serum neutralizing antibody titers against Delta and Omicron variants were compared before and up to three months after the BNT162b2 booster dose, in NH residents without COVID-19 (COVID-19 naive) or with COVID-19 prior to initial vaccination (COVID-19 recovered). Findings 106 NH residents (median [interquartile range] age: 86·5 [81;91] years) were included. The booster dose induced a high increase of anti-spike antibody levels in all subjects (p < 0.0001) and a mild transient increase of specific T cells. Before the booster dose, Delta neutralization was detected in 19% (n = 8/43) and 88% (n = 37/42) of COVID-19 naive and COVID-19 recovered subjects, respectively. Three months after the booster dose, all NH residents developed and maintained a higher Delta neutralization (p < 0·0001). Before the booster dose, Omicron neutralization was detected in 5% (n = 2/43) and 55% (n = 23/42) of COVID-19 naive and COVID-19 recovered subjects, respectively, and three months after, in 84% and 95%, respectively. Neutralizing titers to Omicron were lower than to Delta in both groups with a 35-fold reduction compared to Delta. Interpretation The booster dose restores high neutralization titers against Delta in all NH residents, and at a lower level against Omicron in a large majority of participants. Future studies are warranted to assess if repeated BNT162b2 booster doses or new specific vaccines might be considered for protecting such fragile patients against Omicron and/or future SARS-CoV-2 variants. Funding French government through the Programme Investissement d'Avenir (I-SITE ULNE/ANR-16-IDEX-0004 ULNE) and the Label of COVID-19 National Research Priority (National Steering Committee on Therapeutic Trials and Other COVID-19 Research, CAPNET).Lire moins >

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Projet ANR :

ULNE

Établissement(s) :

Université de Lille
CHU Lille
Institut Pasteur de Lille

Collections :

• Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017
• IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483
• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
• Laboratoire de virologie - ULR 3610
• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2023-10-20T06:07:03Z
2024-02-22T18:01:39Z